What is Zacks Research’s Estimate for MD FY2026 Earnings?

Pediatrix Medical Group, Inc. (NYSE:MD) – Stock analysts at Zacks Research upped their FY2026 earnings estimates for shares of Pediatrix Medical Group in a note issued to investors on Tuesday, August 18th. Zacks Research analyst Team now anticipates that the company will post earnings of $2.11 per share for the year, up from their prior forecast of $2.02. The consensus estimate for Pediatrix Medical Group’s current full-year earnings is $2.15 per share. Zacks Research also issued estimates for Pediatrix Medical Group’s Q2 2027 earnings at $0.53 EPS.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. The company had revenue of $487.78 million for the quarter, compared to analysts’ expectations of $478.49 million. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The firm’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.53 earnings per share.

MD has been the topic of several other research reports. Truist Financial boosted their price target on Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Jefferies Financial Group downgraded Pediatrix Medical Group from a “buy” rating to a “hold” rating and increased their price objective for the stock from $27.00 to $28.00 in a report on Wednesday. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 price objective on shares of Pediatrix Medical Group in a research note on Wednesday, August 5th. UBS Group lifted their price target on Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, August 6th. Finally, Mizuho set a $24.00 price target on Pediatrix Medical Group in a research report on Friday, May 8th. One analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and an average target price of $25.00.

Pediatrix Medical Group Trading Down 0.2%

NYSE:MD opened at $26.16 on Friday. The company has a market capitalization of $2.13 billion, a P/E ratio of 12.52 and a beta of 0.66. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32. The stock’s 50 day moving average price is $25.72 and its 200 day moving average price is $22.95. Pediatrix Medical Group has a 52 week low of $15.69 and a 52 week high of $27.94.

Hedge Funds Weigh In On Pediatrix Medical Group

Several institutional investors and hedge funds have recently modified their holdings of MD. BlackRock Inc. acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter worth approximately $347,383,000. Dimensional Fund Advisors LP grew its stake in Pediatrix Medical Group by 8.1% during the first quarter. Dimensional Fund Advisors LP now owns 3,856,915 shares of the company’s stock worth $82,496,000 after buying an additional 287,696 shares in the last quarter. Wasatch Advisors LP increased its holdings in Pediatrix Medical Group by 21.9% in the 2nd quarter. Wasatch Advisors LP now owns 2,498,884 shares of the company’s stock valued at $63,297,000 after buying an additional 448,360 shares during the period. Geode Capital Management LLC raised its position in shares of Pediatrix Medical Group by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 2,181,712 shares of the company’s stock valued at $46,674,000 after buying an additional 14,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Pediatrix Medical Group by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,552,585 shares of the company’s stock worth $33,210,000 after acquiring an additional 105,345 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Pediatrix Medical Group

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Zacks raised several earnings forecasts: Estimates increased for FY2026 EPS to $2.11 from $2.02, FY2027 EPS to $2.10 from $1.94, and FY2028 EPS to $2.04 from $1.88. Quarterly estimates were also lifted for Q1 2027, Q2 2027, Q3 2027 and Q4 2027. The revisions suggest improving confidence in Pediatrix’s future profitability.
• Positive Sentiment: Momentum sentiment remains supportive. A Zacks article characterized Here’s Why Pediatrix Medical Group Is a Strong Momentum Stock Pediatrix Medical Group as a strong momentum stock, reinforcing the recent positive trend in investor sentiment.
• Neutral Sentiment: Forecasts remain close to consensus. Zacks’ FY2026 estimate of $2.11 per share is slightly below the current consensus of $2.15, indicating that the upgrades are constructive but do not represent a major change in the broader earnings outlook.
• Negative Sentiment: One longer-term estimate was reduced. Zacks lowered its Q1 2028 EPS forecast to $0.34 from $0.36, partially offsetting the other upward revisions and highlighting some uncertainty around longer-term quarterly performance.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.